Rep. Marjorie Taylor Greene Buys GSK plc (NYSE:GSK) Shares

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of GSK plc NYSE: GSK. In a filing disclosed on November 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in GSK stock on November 25th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 11/25/2024.
• Purchased $1,001 - $15,000 in shares of Costco Wholesale NASDAQ: COST on 11/25/2024.
• Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 11/25/2024.
• Purchased $1,001 - $15,000 in shares of NextEra Energy NYSE: NEE on 11/25/2024.
• Purchased $1,001 - $15,000 in shares of Home Depot NYSE: HD on 11/25/2024.
• Purchased $1,001 - $15,000 in shares of Berkshire Hathaway NYSE: BRK.B on 11/25/2024.
• Purchased $1,001 - $15,000 in shares of Nestlé OTCMKTS: NSRGY on 11/25/2024.
• Purchased $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 11/25/2024.
• Purchased $1,001 - $15,000 in shares of Lam Research NASDAQ: LRCX on 11/25/2024.
• Purchased $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 11/25/2024.

GSK Stock Performance

GSK stock traded down $0.20 during mid-day trading on Friday, reaching $34.13. The company had a trading volume of 2,051,795 shares, compared to its average volume of 4,144,134. The stock's 50-day simple moving average is $37.29 and its two-hundred day simple moving average is $40.01. The stock has a market capitalization of $70.74 billion, a P/E ratio of 22.16, a P/E/G ratio of 1.31 and a beta of 0.66. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. GSK plc has a one year low of $32.83 and a one year high of $45.92.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This is an increase from GSK's previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.60%. The ex-dividend date of this dividend is Friday, November 15th. GSK's dividend payout ratio is presently 99.35%.

Wall Street Analyst Weigh In

GSK has been the topic of several analyst reports. Guggenheim lowered shares of GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Argus raised GSK to a "strong-buy" rating in a research report on Wednesday, August 7th. Barclays upgraded shares of GSK to a "hold" rating in a research report on Tuesday, August 27th. Finally, Jefferies Financial Group lowered GSK from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. The trade was a 19.97 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On GSK

Hedge funds have recently bought and sold shares of the business. FMR LLC lifted its stake in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the last quarter. Primecap Management Co. CA raised its holdings in GSK by 13.9% in the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company's stock worth $558,689,000 after acquiring an additional 1,773,020 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in GSK during the 2nd quarter worth $52,487,000. Fisher Asset Management LLC boosted its holdings in GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock valued at $759,425,000 after acquiring an additional 870,449 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its holdings in GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock valued at $144,803,000 after acquiring an additional 833,080 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2025. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2024 election. Marjorie Taylor Greene earned a bachelor's degree in business administration from the University of Georgia. Greene's career experience includes co-owning construction company Taylor Commercial and founding and owning a CrossFit gym.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.